M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B BioSpaceWhile peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.M&A / DealsMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioSpace While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver InjuriesNext: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026